Low Frequency of Drug-Resistant virus did not Affect the Therapeutic Efficacy in Daclatasvir plus Asunaprevir Therapy in Patients with Chronic HCV Genotype-1 Infection
暂无分享,去创建一个
S. Toyooka | H. Shiraha | A. Takaki | Kazuhide Yamamoto | T. Matsubara | H. Kinugasa | F. Ikeda | Y. Iwasaki | K. Takaguchi | Chizuru Mori
[1] H Abe,et al. Emergence of resistant variants detected by ultra‐deep sequencing after asunaprevir and daclatasvir combination therapy in patients infected with hepatitis C virus genotype 1 , 2015, Journal of viral hepatitis.
[2] G. Raimondo,et al. Lack of the NS5B S282T Mutation in HCV Isolates from Liver Tissue of Treatment-Naive Patients with HCV Genotype-1b Infection , 2015, Antiviral therapy.
[3] K. Yoshioka,et al. The clinical features of patients with a Y93H variant of hepatitis C virus detected by a PCR invader assay , 2015, Journal of Gastroenterology.
[4] L. Yamasaki,et al. Hepatitis C virus molecular evolution: transmission, disease progression and antiviral therapy. , 2014, World journal of gastroenterology.
[5] 義之 鈴木,et al. PCR-Invaderを用いたHCV NS5A領域Y93H変異検出法の開発 , 2014 .
[6] K. Chayama,et al. Daclatasvir Plus Asunaprevir for Chronic HCV Genotype 1b Infection , 2014, Hepatology.
[7] Ralf Bartenschlager,et al. The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection , 2013, Nature Reviews Microbiology.
[8] Kenji Ikeda,et al. Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options. , 2013, Journal of hepatology.
[9] Kenji Ikeda,et al. Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir. , 2013, Journal of hepatology.
[10] K. Chayama,et al. Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b–infected null responders , 2012, Hepatology.
[11] Geoffrey Dusheiko,et al. Telaprevir for previously untreated chronic hepatitis C virus infection. , 2011, The New England journal of medicine.
[12] O. Weiland,et al. Telaprevir for retreatment of HCV infection. , 2011, The New England journal of medicine.
[13] Sprint Investigators,et al. Boceprevir for Untreated Chronic HCV Genotype 1 Infection , 2011 .
[14] Stefan Zeuzem,et al. Boceprevir for previously treated chronic HCV genotype 1 infection. , 2011, The New England journal of medicine.
[15] K. Tadokoro,et al. Rapid detection of drug-resistant mutations in hepatitis B virus by the PCR-Invader assay. , 2011, Journal of virological methods.
[16] M. Manns,et al. Boceprevir for untreated chronic HCV genotype 1 infection. , 2011, The New England journal of medicine.
[17] Min Gao,et al. Resistance Analysis of the Hepatitis C Virus NS5A Inhibitor BMS-790052 in an In Vitro Replicon System , 2010, Antimicrobial Agents and Chemotherapy.